Trial Profile

Randomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121)

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Didanosine; Efavirenz; HIV protease inhibitors; Indinavir; Lamivudine; Lamivudine/zidovudine; Lopinavir; Lopinavir/ritonavir; Nevirapine; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Ritonavir; Tenofovir disoproxil fumarate; Zidovudine
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms HIPPOCAMPE

07 Dec 2009 Results from a substudy evaluating antiretroviral resistance were presented at the 12th European AIDS Conference.
05 Jun 2009 New trial record.
15 Nov 2005 Biomarkers information updated

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com